GQ Bio Therapeutics to attend the OARSI - Osteoarthritis Research Society International World Congress (April 18 – 21 2024, Vienna)🤝🇦🇹 The OARSI World Congress is the premier annual international forum for those involved in OA research and treatment. Meet GQ Bio Therapeutics’ COO and Co-founder Stanislav Plutizki to talk about our high-capacity #genetherapy vector platform (HCAd) and its use for transformative gene therapies for prevalent diseases such as #osteoarthritis and intervertebral #discdegeneration.
GQ Bio Therapeutics
Biotechnologie
High-Capacity Gene Therapy Vector Platform to Address Prevalent Diseases
Info
GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium.
- Website
-
http://www.gq-biotx.com
Externer Link zu GQ Bio Therapeutics
- Branche
- Biotechnologie
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Hamburg
- Art
- Privatunternehmen
- Gegründet
- 2012
- Spezialgebiete
- biotechnology, gene therapy, osteoarthritis, drug development, human medicine, animal health und musculoskeletal disease
Orte
-
Primär
Wegbeschreibung
Harburger Schlossstr. 6-12
Hamburg, 21079, DE
-
Wegbeschreibung
Im Biotechnologiepark 3
Luckenwalde, Brandenburg 14943, DE
Beschäftigte von GQ Bio Therapeutics
Updates
-
GQ Bio Therapeutics' CEO Kilian Guse and head of bioinformatics Brian Dawson will discuss our #AI approach for capsid engineering of gene therapy vectors at the FoldForum in Hamburg April 24. Looking forward to seeing you there! https://lnkd.in/e5Ez9NFD
Medical Doctor, Surgeon, Scientist, Entrepreneur, Investor, Medtech and Biotech Enthusiast
🌟 Save the Date für FoldForum # 2: Revolution der Proteinwissenschaften durch Deeptech! presented by AUFBRUCH.Hamburg 🚀 Health Panels und Artificial Intelligence Center Hamburg (ARIC)🌟 📅 Wann: 24.04.2024 um 16.00 Uhr. Du bist herzlich eingeladen, bei einem faszinierenden Abend dabei zu sein, an dem sich alles um neueste Deeptech-Entwicklungen in den Proteinwissenschaften dreht. Wo: DeepTech Campus (für Details siehe LinkedIn Veranstaltung) 🔬 Moderation: Natalie Rotermund und Dr. Dr. Alexander T. El Gammal (MD, PhD) 🗣 Speaker: Kilian Guse (CEO, GQ Bio Therapeutics), Prof. Dr. Jens Bosse, Dr. Felix Tobola, und Jakob Mertes (Machine Learning Engineer, ARIC) 🚀 Lasst Euch inspirieren von den führenden Köpfen in Biotechnologie, KI-Engineering im Bereich Proteomics und entdecke, wie Innovationen die Grenzen des Möglichen neu definieren. 👥 Perfekt für Netzwerker und Innovationsenthusiasten! Trefft Experten und Gleichgesinnten aus der DeepTech- Branche. 🎟 Registrierung: Kostenlos! Melde dich über den Eventim-Link in der LinkedIn Veranstaltung an und sichere dir deinen Platz. #FoldForum #ProteinScience #Deeptech #Biotech #AI #Networking #Innovation #AUFBRUCHHamburg #ARIC 🔗🔬🧬 Verpasse nicht die Chance, Teil dieser zukunftsweisenden Veranstaltung zu sein!
Dieser Inhalt ist hier nicht verfügbar.
Mit der LinkedIn App können Sie auf diese und weitere Inhalte zugreifen.
-
Congratulations to the Pacira BioSciences, Inc. team for receiving RMAT designation for PCRX-201! This is a great achievement as the RMAT designation was based on strong clinical data in knee #osteoarthritis patients and can expedite the further development of PCRX-201, which was originally developed by GQ Bio Therapeutics. Also, PCRX-201 marks the first-ever #genetherapy to receive RMAT designation – a significant step forward for the high-capacity adenoviral vector technology! https://lnkd.in/dSyb283Y
-
-
🗣 Let’s talk about #GeneTherapy in Belgium 🇧🇪 Meet GQ Bio Therapeutics’ COO and Co-founder Stanislav Plutizki at CHIREC Hospital Group’s International Symposium on Regenerative Medicine in Orthopedic Surgery in Brussels/Belgium on Saturday 23rd September. Stanislav Plutizki will showcase GQ Bio Therapeutics’ high-capacity #genetherapy vector platform (HCAd) and its transformative gene therapies for prevalent diseases such as #osteoarthritis and intervertebral #discdegeneration.
-
-
The US Patent and Trademark Office grants patent for GQ Bio Therapeutics’ lead gene therapy candidate GQ-501 for treatment of osteoarthritis. Securing intellectual protection in the US, which is the largest osteoarthritis market, represents a major milestone for GQ Bio. The patent for this technology was already granted in 2020 in Europe, which is the second largest market. #genetherapy #osteoarthritis
-
-
GQ Bio Therapeutics Closes Collaboration Deal with Pacira BioSciences, Inc. for Development of a Commercial-Scale Manufacturing Process for High-Capacity Adenoviral Vectors. As part of the multi-million-dollar collaboration, GQ Bio will lead the process development, which will take place at GQ Bio’s R&D facility in Germany, as well as contract research organizations. While the development of the manufacturing process is initially focused on PCRX-201, GQ Bio will be able to use the process for its entire HCAd platform including the lead candidate GQ-501. Read more: http://bit.ly/44dsYkf